Kinon Bruce J, Hill Angela L, Liu Hong, Kollack-Walker Sara
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Int J Neuropsychopharmacol. 2003 Jun;6(2):97-102. doi: 10.1017/S1461145703003389.
The objective of this study was to determine if the orally disintegrating tablet formulation of olanzapine, Zyprexa Zydis, would facilitate antipsychotic medication compliance in acutely ill, non-compliant patients. Eighty-five acutely ill patients with schizophrenia or schizoaffective disorder who met medication non-compliance criteria received open-label olanzapine orally disintegrating tablets (1020 mgd) for up to 6 wk. Improvement in medication compliance was assessed using various rating scales to measure changes in psychopathology, medication-taking and compliance attitudes, and nursing care burden. Safety variables were also measured. Significant improvement from baseline was demonstrated in the Positive and Negative Syndrome Scale total score at Week 1 and subsequently (p0.001). Significant improvement from baseline was also seen in various scales measuring medication compliance, attitude, and nursing care burden (p0.05). Olanzapine orally disintegrating tablets were well-tolerated. Olanzapine orally disintegrating tablets may benefit acutely ill, non-compliant schizophrenic patients by facilitating acceptance of active antipsychotic drug therapy.
本研究的目的是确定奥氮平口崩片（再普乐口崩片）是否会促进急性发病、不依从治疗的患者对抗精神病药物的依从性。85例符合药物治疗不依从标准的急性发病的精神分裂症或分裂情感性障碍患者接受了开放标签的奥氮平口崩片（10 - 20mg/天）治疗，为期6周。使用各种评定量表评估药物依从性的改善情况，以测量精神病理学、服药及依从态度和护理负担的变化。还对安全性变量进行了测量。在第1周及随后各周，阳性和阴性症状量表总分较基线有显著改善（p<0.001）。在测量药物依从性、态度和护理负担的各种量表中，也可见较基线有显著改善（p<0.05）。奥氮平口崩片耐受性良好。奥氮平口崩片可能通过促进急性发病、不依从治疗的精神分裂症患者接受有效的抗精神病药物治疗而使其获益。
